Vous êtes sur la page 1sur 4

Kelly Carles-Kinch, Ph.D.

Work Address: Home Address:
708 Quince Orchard Rd. 19627 Hoover Farm Dr.
Suite 240 Laytonsville, MD 20882
Gaithersburg, MD 20878 240-683-1277
301-944-2339 kcb0336e@westpost.net
kcarles@functional-genetics.com Date and Place of Birth:
November 18, 1967
Wright-Patterson AFB, USA
2009-present Functional Genetics, Inc.

Gaithersburg, MD
Program Manager, Preclinical Development: May 2009-present
Part-time (currently 30 hrs weekly)
* Program management of contract with Department of Defense to
develop anti-viral small molecule therapeutics.
* Oversight of all vendor activities supporting pre-clinical
development of compounds within the FGI-102 program.
* Coordination of animal studies at USAMRIID, NIH, and elsewhere to
achieve proof of concept.
* IND expected in Q1 2011.
* Management of a collaboration with Elanco Therapeutics (a
subsidiary of Eli Lilly) to develop anti-viral therapeutics for
2002-2009 MedImmune LLC (A subsidiary of Astra Zeneca
Pharmaceuticals), Gaithersburg, MD
Dept. of Research:

Director, Research Operations and Portfolio Management: May 2005-

May 2009 (promoted twice while leading function)
The Research Operations and Portfolio Management Dept. assists the
greater Research Organization achieve strategic goals by providing
project & portfolio planning, resource management, and operational
* Creation of Project, Portfolio and Alliance Management functions
for Research
* Leadership of project management group that supports Research
* Development of tools and systems to assess portfolio risk, shape,
and progression.
* Management of multiple alliances with partnering companies
* Implementation of stage-gate system for project management
* Implementation of resource management into Research Department
* Organization of monthly portfolio reviews to oversee resource
* Member of steering committee for Planisware (OPX2) implementation
at MedImmune
* Management of a $200M+ research budget
* Tracking and follow through on contractual obligations with
collaborators, alliances, vendors, etc.
* Primary liaison between Research and other supporting functions
(legal, finance, procurement, etc); tasked with building
relationships, and thus improving processes and support to
* Creation of a Research Information Systems function within
* Creation of a Lab Operations function within Research
* Creation of a non-clinical scientific writing function within
* Member of numerous initiates to improve processes and policies,
* SAP Project Implementation
* Scientific Ladder Development Initiative
* Records Retention/Legacy Migration Policy Projects
* Advanced Templates Project
* PDC/PDT (MedI project governance) `best practices' initiatives
Dept. of Research: Research Scientist
Scientist II: January 2002-June 2004
Scientist III: June 2004-May 2005
Primary focus included new target discovery and widening use of
existing therapeutic targets to cancer, inflammatory and respiratory
* Project Team Leader, EphA4 Oncology Program
* Project Team Leader, EphA2 Inflammatory Disease Program

1999-2001: Purdue University, West Lafayette, IN

Department of Basic Medical Sciences
Research Scientist
* Validated the EphA2 tyrosine kinase as a target for therapeutic
* Teaching and educational achievements
* Lecturer of pharmacology/microbiology in medical and veterinary
* Project Manager, BioScope Initiative for computer-based biology
* Author of educational material, BioScope Initiative
1997-1999: Purdue University, West Lafayette, IN.
Post-Doctoral Research Fellow
* Analysis of signaling events that control cytokinesis in
Aspergillus nidulans (with Dr. John Hamer, Department of Biology).
* Studies of the HBV-X protein and its role in liver carcinogenesis
(with Dr. Ourania Andrisani, Department of Basic Medical
1990-1996: Duke University Medical Center, Durham, NC
Department of Microbiology and Immunology
Ph.D. in Microbiology and Immunology
1989-1990: Ohio Wesleyan University, Delaware, OH
Department of Zoology
Bachelor of Arts (GPA: 3.95 of 4)

1988-1989: Aberdeen University, Aberdeen, Scotland.

Department of Zoology
Exchange Student
* Drug Information Association
* Project Management Institution; PMP certification received in 2010
Hu, M., Carles-Kinch, K., Zelinski, D.P., and Kinch, M.S. 2004. EphA2
induction of fibronectin creates a permissive microenvironment for
malignant cells. Mol. Cancer Res. 2:533-40.
Coffman, K.T., Hu, M., Carles-Kinch, K., Tice, D., Donacki, N.,
Munyon, K., Kifle, G., Woods, R., Langermann, S., Kiener, P., and
Kinch, M.S. 2003. Differential EphA2 epitope display on normal versus
malignant cells. Cancer Res. 63, 7907-7912.

Kinch, M., and Carles-Kinch, K. 2003. Overexpression and functional

alterations of the EphA2 tyrosine kinase in cancer. Clinical and
Experimental Metastasis, 20, 59-68.
Carles-Kinch, K., Kilpatrick, K., Stewart, J., and Kinch, M.S. 2002.
Antibody targeting of the EphA2 tyrosine kinase inhibits malignant
cell behavior. Cancer Res., 62, 2840-2847.
Hess, A.R., Seftor, E.A., Gardner, L.M.G., Carles-Kinch, K.,
Schneider, G.B., Seftor, R.E., Kinch, M.S., and Hendrix, M.J.C. 2001.
Molecular regulation of tumor cell vasculogenic mimicry by tyrosine
phosphorylation: Role of epithelial cell kinase (Eck/EphA2). Cancer
Res., 61, 3250-3255.
Carles-Kinch, K., George, J.W., and Kreuzer, K.N. 1997. Bacteriophage
T4 UvsW protein is a helicase involved in recombination, repair, and
regulation of DNA replication origins. EMBO J., 16, 4142-4151.
Carles-Kinch, K. and Kreuzer, K.N. 1997. RNA-DNA hybrid formation at a
bacteriophage T4 replication origin. J. Mol. Biol., 266, 915-926.
Neece, S.H., Carles-Kinch, K., Tomso, D.J., and Kreuzer, K.N. 1996.
Role of recombinational repair in sensitivity to an antitumor agent
that inhibits bacteriophage T4 type II DNA topoisomerase. Molecular
Microbiology, 20, 1145-1154.
Kinch, M.S., Carles-Kinch, K. Use of modulators of EphA2 and EphrinA1
for the treatment and prevention of infections. US 2006/0121043 & WO
Kinch, M.S., Carles-Kinch, K. Modulators of EphA2 and EphrinA1 for the
treatment of fibrosis-related disease. US 2006/0122138 & WO
Dall'Acqua, W., Damschroder, M., Kinch, M.S., Carles-Kinch, K.
Modulation of antibody specificity by tailoring the affinity to
cognate antigens. US 2006/0121042 & WO 2006/047639.
Kinch, M.S., Carles-Kinch, K. Use of EphA4 and modulator of EphA4 for
diagnosis, treatment and prevention of cancer. US 2005/0013819 & WO
Kinch, M.S., Carles-Kinch, K., Stewart, J.C. EphA2 monoclonal
antibodies and methods of use thereof. US 2005/0152899 & WO
Kinch, M.S., Carles-Kinch, K., Kiener, P., Langermann, S., McCarthy,
M., Tice, D., Woessner, R. Combination therapy for the treatment and
prevention of cancer using EphA2, PCDGF and HAAH. WO 05/016381.
Kinch, M.S., Carles-Kinch, K., Kiener, P., Langermann, S. EphA2
monoclonal antibodies and methods of use thereof. US 2004/0028685 & WO
Kinch, M.S., Carles-Kinch, K. EphA2 agonistic monoclonal antibodies
and methods of use thereof. WO 2004/014292.